GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » 9-Day RSI

Moderna (Moderna) 9-Day RSI

: 40.92 (As of Today)
View and export this data going back to 2018. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-19), Moderna's 9-Day RSI is 40.92.

The industry rank for Moderna's 9-Day RSI or its related term are showing as below:

MRNA's 9-Day RSI is ranked worse than
55.3% of 1575 companies
in the Biotechnology industry
Industry Median: 39.06 vs MRNA: 40.92

Competitive Comparison

For the Biotechnology subindustry, Moderna's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna 9-Day RSI Distribution

For the Biotechnology industry and Healthcare sector, Moderna's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Moderna's 9-Day RSI falls into.



Moderna  (NAS:MRNA) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moderna  (NAS:MRNA) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Moderna 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Moderna's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (Moderna) Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Stephen Hoge officer: President C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock officer: Chief Financial Officer 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger officer: Chief Legal Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay officer: Chief Commercial Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel director, officer: Chief Executive Officer 320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres officer: See Remarks C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline officer: Chief Financial Officer 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez officer: See Remarks C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan director AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson officer: General Counsel and Secretary MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115

Moderna (Moderna) Headlines

From GuruFocus

Q3 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc R&D Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Science & Technology Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at Jefferies Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Vaccines Day Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024